Xopenex (levalbuterol) is a brand-name inhaled medication prescribed to treat and help prevent difficulty breathing associated with bronchospasm. Xopenex comes in two forms: a solution for use with a ...
COPD - Chronic Obstructive Pulmonary Disease - including chronic bronchitis and emphysema, is characterized by breathing difficulty due to partial blockage of the bronchial tubes. Asthma is a chronic ...
Verywell Health on MSN
Levalbuterol vs. Albuterol: How Do They Differ?
About one out of 12 people in the United States has asthma. Asthma is a chronic (long-term) lung condition in which airways ...
Levalbuterol (as tartrate) (single-isomer albuterol) 45mcg/inh; metered dose inhaler; CFC-free. Do not exceed recommended dose. Monitor for increased need; if inadequate control, reevaluate and ...
"Xopenex in the hospital setting is a safe, and effective alternative to racemic albuterol in treating the bronchial smooth muscle spasm associated with diseases such as COPD and asthma," Truitt said.
Watson Pharmaceuticals has launched an authorized generic version of Xopenex (levalbuterol HCl) Inhalation Solution. This is part of an agreement Watson has with Sunovion Pharmaceuticals, who ...
Teva Launches Generic Xopenex Concentrate Teva announced the launch of Levalbuterol Inhalation Solution, the generic version of Xopenex Inhalation Solution Concentrate. Teva announced the launch of ...
DUBLIN--(BUSINESS WIRE)--The "Xopenex - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Xopenex Drug Insight, 2019 highlights the drug marketed details and the Global ...
Xopenex is approved for patients aged 6 years and above for the treatment of bronchospasm caused by asthma and chronic obstructive pulmonary disease. We note that Dr. Reddy's is a late entrant in the ...
March 17, 2005 — The U.S. Food and Drug Administration (FDA) has approved a new indication for temozolomide, allowing its use in the first-line treatment of glioblastoma multiforme; orphan drug status ...
NEW YORK, March 10 (Reuters) - Sepracor Inc said on Tuesday it had reached a settlement that will allow Israeli drugmaker Teva Pharmaceutical Industries Ltd to begin selling a generic form of Sepracor ...
NEW YORK, Oct 28 (Reuters) - Sepracor Inc posted a sharp decline in third-quarter profit on Tuesday, missing Wall Street estimates, as lower reimbursement rates from Medicare hurt sales of its asthma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results